Abstract:Predictive approaches such as virtual screening have been used in drug discovery with the objective of reducing developmental time and costs. Current machine learning and network-based approaches have issues related to generalization, usability, or model interpretability, especially due to the complexity of target proteins' structure/function, and bias in system training datasets. Here, we propose a new method "DRUIDom" (DRUg Interacting Domain prediction) to identify bio-interactions between drug candidate compounds and targets by utilizing the domain modularity of proteins, to overcome problems associated with current approaches. DRUIDom is composed of two methodological steps. First, ligands/compounds are statistically mapped to structural domains of their target proteins, with the aim of identifying their interactions. As such, other proteins containing the same mapped domain or domain pair become new candidate targets for the corresponding compounds. Next, a million-scale dataset of small molecule compounds, including those mapped to domains in the previous step, are clustered based on their molecular similarities, and their domain associations are propagated to other compounds within the same clusters. Experimentally verified bioactivity data points, obtained from public databases, are meticulously filtered to construct datasets of active/interacting and inactive/non-interacting drug/compound-target pairs (~2.9M data points), and used as training data for calculating parameters of compound-domain mappings, which led to 27,032 high-confidence associations between 250 domains and 8,165 compounds, and a finalized output of ~5 million new compound-protein interactions. DRUIDom is experimentally validated by syntheses and bioactivity analyses of compounds predicted to target LIM-kinase proteins, which play critical roles in the regulation of cell motility, cell cycle progression, and differentiation through actin filament dynamics. We showed that LIMK-inhibitor-2 and its derivatives significantly block the cancer cell migration through inhibition of LIMK phosphorylation and the downstream protein cofilin. One of the derivative compounds (LIMKi-2d) was identified as a promising candidate due to its action on resistant Mahlavu liver cancer cells. The results demonstrated that DRUIDom can be exploited to identify drug candidate compounds for intended targets and to predict new target proteins based on the defined compound-domain relationships. Datasets, results, and the source code of DRUIDom are fully-available at: https://github.com/cansyl/DRUIDom.

Combining Molecular Docking and Graph Convolutional Network to Discover Potential Selective Limk1 Inhibitors

Graph convolutional network approach to investigate potential selective Limk1 inhibitors

Discovery of Rho-kinase inhibitors by docking-based virtual screening

An Integrated in Silico Method to Discover Novel Rock1 Inhibitors: Multi- Complex-Based Pharmacophore, Molecular Dynamics Simulation and Hybrid Protocol Virtual Screening.

Discovery Of Novel Rock1 Inhibitors Via Integrated Virtual Screening Strategy And Bioassays

Theoretical Study on the Interaction of Pyrrolopyrimidine Derivatives As LIMK2 Inhibitors: Insight into Structure-Based Inhibitor Design.

Discovery and Optimization of Triazine Derivatives As ROCK1 Inhibitors: Molecular Docking, Molecular Dynamics Simulations and Free Energy Calculations

Development and evaluation of an integrated virtual screening strategy by combining molecular docking and pharmacophore searching based on multiple protein structures.

Docking-informed machine learning for kinome wide affinity prediction

Identification of inhibitors for neurodegenerative diseases targeting dual leucine zipper kinase through virtual screening and molecular dynamics simulations

Identifying dual leucine zipper kinase (DLK) inhibitors using e-pharamacophore screening and molecular docking

LCK-SafeScreen-Model: An Advanced Ensemble Machine Learning Approach for Estimating the Binding Affinity between Compounds and LCK Target

Identifying Potential Dual Inhibitory Candidates for Non-Small Cell Lung Cancer Through Molecular Docking, 3D-QSAR Pharmacophore-based Virtual Screening, Comparative Molecular Field and Similarity Indices Analysis Modeling

A Multi-Target Docking System of Human Kinome

Feasibility of using molecular docking-based virtual screening for searching dual target kinase inhibitors

Combining AI and traditional screening for discovery of a potent ROCK2 inhibitor against lymphoma

Identifying Isoononin and Candidissiol as Rho-associated protein kinase 1 (ROCK1) inhibitors: a combined virtual screening and MD simulation approach

Identification of potential CAMKK2 inhibitors based on virtual screening and molecular dynamics simulation

Protein domain-based prediction of drug/compound-target interactions and experimental validation on LIM kinases

A Novel Graph Neural Network Methodology to Investigate Dihydroorotate Dehydrogenase Inhibitors in Small Cell Lung Cancer

An integrated docking and molecular dynamics simulation approach to discover potential inhibitors of activin receptor-like kinase 1